News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,315 Results
Type
Article (41571)
Company Profile (293)
Press Release (656451)
Section
Business (209775)
Career Advice (2062)
Deals (36556)
Drug Delivery (89)
Drug Development (82592)
Employer Resources (170)
FDA (16415)
Job Trends (15331)
News (354524)
Policy (33792)
Tag
Academia (2573)
Africa (773)
Alliances (50961)
Alzheimer's disease (1156)
Approvals (16340)
Arizona (180)
Artificial intelligence (78)
Asia (39659)
Australia (6320)
Bankruptcy (361)
Best Places to Work (11401)
Biosimilars (67)
Biotechnology (188)
C2C Services and Suppliers (79824)
California (1809)
Canada (912)
Cancer (454)
Career advice (1724)
Cell therapy (119)
China (144)
Clinical research (64655)
Collaboration (132)
Colorado (73)
Compensation (77)
Connecticut (72)
COVID-19 (2557)
Cystic fibrosis (74)
Data (276)
Diabetes (80)
Diagnostics (6049)
Drug pricing (69)
Earnings (85320)
Employer resources (145)
Europe (84226)
Events (110573)
Executive appointments (141)
FDA (16620)
Florida (256)
Funding (138)
Gene therapy (97)
GLP-1 (536)
Government (4403)
Healthcare (18788)
Hotbed/Location (489854)
Illinois (252)
Indiana (150)
Infectious disease (2584)
Inflammatory bowel disease (93)
Interviews (317)
IPO (16466)
Job creations (4044)
Job search strategy (1483)
Kansas (94)
Layoffs (414)
Legal (8294)
Lung cancer (99)
Manufacturing (89)
Maryland (384)
Massachusetts (1501)
Medical device (13147)
Medtech (13152)
Mergers & acquisitions (19926)
Metabolic disorders (252)
Michigan (124)
Minnesota (213)
Neuroscience (1300)
New Jersey (562)
New York (570)
NextGen Class of 2024 (6607)
Non-profit (4503)
North Carolina (593)
Northern California (805)
Obesity (150)
Ohio (104)
Opinion (194)
Patents (69)
Pennsylvania (572)
People (57768)
Pharmaceutical (85)
Phase I (19945)
Phase II (28446)
Phase III (21392)
Pipeline (105)
Postmarket research (2637)
Preclinical (8488)
Press Release (68)
Rare diseases (133)
Real estate (6230)
Recruiting (65)
Regulatory (22009)
Research institute (2355)
Resumes & cover letters (355)
South America (1151)
Southern California (729)
Startups (3708)
Texas (228)
United States (8370)
Vaccines (485)
Washington State (248)
Weight loss (134)
Date
Today (76)
Last 7 days (706)
Last 30 days (2151)
Last 365 days (37775)
2024 (26162)
2023 (40638)
2022 (51809)
2021 (56338)
2020 (54799)
2019 (47408)
2018 (35786)
2017 (33155)
2016 (32687)
2015 (38633)
2014 (32542)
2013 (27652)
2012 (29748)
2011 (30496)
2010 (28517)
698,315 Results for "titan pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Titan Pharmaceuticals Enters Into Merger Agreement With KE Sdn. Bhd.
August 20, 2024
·
7 min read
Biotech Bay
Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria
Titan Pharmaceuticals, Inc. announced that by letter dated January 24, 2024, the Company was notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum $1.00 bid price requirement and otherwise satisfies all applicable criteria for continued listing on The Nasdaq Capital Market.
January 25, 2024
·
2 min read
Biotech Bay
Titan Pharmaceuticals Announces Reverse Stock Split and Ratio - December 28, 2023
Titan Pharmaceuticals, Inc. announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company’s common stock, which will be effective following the filing of an amendment to the Company’s Amended and Restated Certificate of Incorporation.
December 28, 2023
·
3 min read
Deals
Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd.
September 18, 2023
·
3 min read
Biotech Bay
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
Titan Pharmaceuticals, Inc. announced that it has entered into an Asset Purchase Agreement with Fedson, Inc., a Delaware Corporation, for the sale of certain ProNeura assets including Titan’s portfolio of drug addiction products, in addition to other early development programs based on the ProNeura drug delivery technology.
July 27, 2023
·
3 min read
Business
Titan Pharmaceuticals Announces Appointment of Dato’ Seow Gim Shen and Brynner Chaim to the Company’s Board of Directors
Titan Pharmaceuticals, Inc. is pleased to announce the appointments of Dato’ Seow Gim Shen and Brynner Chiam to the Company’s Board of Directors, effective October 12, 2023.
October 16, 2023
·
4 min read
Business
Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that it has granted an exclusive license to Ocular Therapeutix Inc. (“Ocular”) pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States.
December 12, 2022
·
2 min read
Business
UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that it has granted an exclusive license to Ocular Therapeutix Inc. (“Ocular”) pertaining to certain patent applications for ophthalmic uses in both humans and nonhuman animals in the territory of the United States.
December 12, 2022
·
2 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Deals
Titan Pharmaceuticals Provides Shareholder Update
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) is pleased to report that it has entered a non-binding letter of intent to complete a reverse merger with a leading developer in Advanced Air Mobility (AAM) (the “Proposed Reverse Merger”).
December 15, 2022
·
3 min read
1 of 69,832
Next
